These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 21533343)

  • 61. High-performance liquid chromatographic procedure for the determination of a new positive inotropic agent, 3,4-dihydro-6-[4-(3,4-(dimethoxybenzoyl)-1-piperazinyl]-2(1H)- quinolinone, in human plasma and urine.
    Miyamoto G; Sasabe H; Odomi M; Shimizu T
    J Chromatogr; 1985 Mar; 338(2):450-5. PubMed ID: 3998030
    [No Abstract]   [Full Text] [Related]  

  • 62. The treatment with differentiation- and apoptosis-inducing agent, vesnarinone, of a patient with oral squamous cell carcinoma.
    Sato M; Harada K; Yura Y; Azuma M; Kawamata H; Iga H; Tsujimoto H; Yoshida H; Adachi M
    Apoptosis; 1997; 2(3):313-8. PubMed ID: 14646544
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Enhancement of anticancer effects of radiation and conventional anticancer agents by a quinolinone derivative, vesnarinone: studies on human gastric cancer tissue xenografts in nude mice.
    Kawai K; Konishi Y; Izumi K; Sato M; Adachi M; Hozumi M
    Anticancer Res; 1998; 18(1A):405-12. PubMed ID: 9568110
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Induction of apoptosis in human choriocarcinoma cell lines by treatment with 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-quinolinone (vesnarinone).
    Isaka K; Fujito A; Sagawa Y; Yudate T; Nishi H; Ito H; Takayama M
    Oncol Rep; 2002; 9(6):1299-305. PubMed ID: 12375038
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Characteristics of antitumor activity of 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]- 2(1H)-quinolinone (vesnarinone) against a human adenoid squamous carcinoma-forming cell line grown in athymic nude mice.
    Sato M; Harada K; Bando T; Shirakami T; Nakashiro K; Yoshida H; Nakai S; Kawai K; Adachi M
    Cancer Lett; 1995 May; 91(1):1-9. PubMed ID: 7750082
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Differentiation inducing effects of vesnarinone on human glioma cells.
    Tanaka S; Nishihara T; Nagashima T; Kawai K; Nakai S; Adachi M
    J Clin Neurosci; 1997 Jan; 4(1):57-62. PubMed ID: 18638925
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Effect of 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)- quinolinone (vesnarinone) on the growth of gastric cancer cell lines.
    Yokozaki H; Ito R; Ono S; Hayashi K; Tahara E
    Cancer Lett; 1999 Jun; 140(1-2):121-8. PubMed ID: 10403550
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Clinical characteristics of vesnarinone.
    Feldman AM
    Drug Saf; 2004; 27 Suppl 1():1-9. PubMed ID: 15293848
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Vesnarinone: a differentiation-inducing anti-cancer drug.
    Kawamata H; Omotehara F; Nakashiro K; Uchida D; Hino S; Fujimori T
    Anticancer Drugs; 2003 Jul; 14(6):391-5. PubMed ID: 12853878
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The quinolinone derivative vesnarinone potentiates the cytotoxicity of doxorubicin in HL-60 leukemia cells.
    Yamamoto M; Maehara Y; Sakaguchi Y; Kusumoto T; Baba H; Sugimachi K
    Int J Oncol; 1997 Jan; 10(1):53-7. PubMed ID: 21533343
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Precautions for use and adverse effects of vesnarinone: potential mechanisms and future therapies.
    Bertolet BD
    Drug Saf; 2004; 27 Suppl 1():11-8. PubMed ID: 15293849
    [TBL] [Abstract][Full Text] [Related]  

  • 72.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 73.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 74.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 75.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.